BillionToOne, Inc.
BLLN
Rangering i aksjer
#3476
BillionToOne, Inc. is a specialized diagnostics company that innovates by... BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Aksjekurs
$105.11
Markedsverdi
$4.96B
Endring (1 dag)
1.56%
Endring (1 år)
-
Land
US
Handel BillionToOne, Inc. (BLLN)
Kategori
Healthcare
P/S-forhold for BillionToOne, Inc. (BLLN)
P/S-forhold per 2026 TTM: 0
Ifølge BillionToOne, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for BillionToOne, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 5.37 | - |
US
|
|
| 6.29 | - |
US
|
|
| 21.02 | - |
US
|
|
| - | - |
CN
|
|
| 6.67 | - |
US
|
